Oddo BHF - Almirall SA (ALM) Almirall SA : Q4 earnings preview: EBITDA likely to be in the high end of the guidance

Report

Oddo BHF

Juan Ros-Padilla

Almirall SA : Q4 earnings preview: EBITDA likely to be in the high end of the guidance

29/01/2025 1 EN

Underlying

Almirall SA

Almirall is engaged in the acquisition, manufacture, storage, sale and mediation in the sale of pharmaceutical specialties and products and all manner of raw materials used to prepare pharmaceutical specialties and products. Also, Co. acquires, manufactures, storages, sales and mediates in the sale of cosmetics, chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food-industry use, as well as all manner of utensils, complements and accessories for the chemical, pharmaceutical and clinical industries. In addition, Co. is engaged in the acquisition, sale, lease, subdivision and development of land lots, land and properties of all kinds.

See profile

ES0157097017 Madrid Stock Exchange Spain

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Juan Ros-Padilla

Other Reports on these Companies

Sabadell

ALMIRALL: MENSAJES DE LA CONFERENCE CALL RDOS. 4T’24 (ANÁLISIS BANCO SABADELL)

De la conference call Rdos. 4T’24 destacamos:

EUR 50.00

10h / 49m 10h / 49m 1 ES

Sabadell

ALMIRALL: 4Q’24 RESULTS (ANÁLISIS BANCO SABADELL)

4Q'24 vs. 4Q'23 Results Sales: € 258.1 M (+17.4% vs. +12.2% BS(e) and +13.5% consensus); EBITDA: € 50.4 M (+40.8% vs. +29.9% BS(e) and +24.6% consensus); EBIT: € 15.0 M (+177.8% vs. +113.0% BS(e) and +172.2% consensus); Net Profit: € 0.2 M (€ -52.1 M in FY2023 vs. € 2.5 M BS(e) and € 7.9 M consensus); FY2024 vs. FY2023 Results Sales: € 985.7 M (+10.2% vs. +8.9% BS(e) and +9.2% consensus); EBITDA: € 192.6 M (+10.6% vs. +8.4% BS(e) and +7.3% consensus); EBIT: € 53.5 M (+7.4% vs. +0.4% BS(e) and +6.8% consensus); Net Profit: € 10.1 M (€ -38.5 M in FY2023 vs. € 12.4 M BS(e) and € 17.8 M consensus)...

EUR 100.00

13h / 12m 13h / 12m 1 EN

Sabadell

ALMIRALL: RDOS. 4T’24 (ANÁLISIS BANCO SABADELL)

Rdos. 4T'24 vs 4T'23: Ventas: 258,1 M euros (+17,4% vs +12,2% BS(e) y +13,5% consenso); EBITDA: 50,4 M euros (+40,8% vs +29,9% BS(e) y +24,6% consenso); EBIT: 15,0 M euros (+177,8% vs +113,0% BS(e) y +172,2% consenso); BDI: 0,2 M euros (-52,1 M euros en 2023 vs 2,5 M euros BS(e) y 7,9 M euros consenso); Rdos. 2024 vs 2023: Ventas: 985,7 M euros (+10,2% vs +8,9% BS(e) y +9,2% consenso); EBITDA: 192,6 M euros (+10,6% vs +8,4% BS(e) y +7,3% consenso); EBIT: 53,5 M euros (+7,4% vs +0,4% BS(e) y +6,8% consenso); BDI: 10,1 M euros (-38,5 M euros en 2023 vs 12,4 M euros BS(e) y 17,8 M euros consenso)...

EUR 100.00

14h / 9m 14h / 9m 1 ES

Aryzta : Rising from its ashes: from cash-burner to steady compounder

Aryzta is culminating its turnaround, leaving behind its days of debt-fuelled empire building and embracing a culture of disciplined capital allocation. Aryzta has a leadership position in a dynamic food niche (bake-off) which, with an adequate financial structure, is gradually turning into a steady compounder. We initiate with an Outperform rating and a CHF 2.4 target price.

4h / 38m 4h / 38m 1 EN

Carole Braudeau

Carole Braudeau

Credit Morning 02/24/2025

THOM Group: Q1 results in line with expectations, Q2 seems to be off to a good start.|Just East Takeway: Prosus to launch bid for 100% of share capital|Teva: positive Phase 2b results for the divakitug drug, launch of Phase 3 in H2 2025|Saipem: proposal to merge with Subsea7|

11h / 56m 11h / 56m 1 EN

Martin Marandon-Carlhian ... (+2)

Martin Marandon-Carlhian
Stephane Houri

Arm Holdings plc : The steamroller of AI

11h / 59m 11h / 59m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Almirall SA : Q4 earnings preview: EBITDA likely to be in the high end of the guidance

ALMIRALL: MENSAJES DE LA CONFERENCE CALL RDOS. 4T’24 (ANÁLISIS BANCO SABADELL)

ALMIRALL: 4Q’24 RESULTS (ANÁLISIS BANCO SABADELL)

ALMIRALL: RDOS. 4T’24 (ANÁLISIS BANCO SABADELL)

Aryzta : Rising from its ashes: from cash-burner to steady compounder

Credit Morning 02/24/2025

Arm Holdings plc : The steamroller of AI

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe